A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants

Sponsor
Shandong Suncadia Medicine Co., Ltd.
Study ID
NCT07479641
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • Test formulation of HRS-1893 tablet — DRUG
    Test formulation of HRS-1893 tablet, oral.
  • Reference formulation of HRS-1893 tablet — DRUG
    Reference formulation of HRS-1893 tablet, oral.

Study Details

This study will investigate the bioequivalence between two formulations of HRS-1893 tablets. Safety and tolerability will also be assessed.

Key Dates

Start date
Apr 14, 2026
Status verified
Apr 2026
Primary completion
Jun 30, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
36 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: HRS-1893 test formulation group
  • Experimental: HRS-1893 reference formulation group

Primary Outcome Measure

Peak concentration (Cmax). [ Time Frame: From Day 1 to Day 17. ]

Central Contacts

Related Studies